News on the latest discoveries and experiments for the treatment and diagnosis of Cardiomyopathies.

Anticoagulants and antiaggregants in pregnancy

In women with different types of cardiomyopathy and who take antiplatelet or anticoagulant drugs, there is a risk of maternal or fetal hemorrhages and fetal malformations. For those who decide to embark on a pregnancy it is therefore necessary to request consultation in reference centers in order to carefully evaluate the risk and possible alternative therapy when possible. Here are some recommendations.

June 25 2024|

My experience in San Diego where new therapies are explored

At the University of California San Diego (UCSD), the first gene therapy for a hereditary heart disease was developed: Danon disease, characterized by the accumulation of glycogen, due to variants in the gene that codes for a protein necessary for the elimination of cell phone waste. The type of gene therapy developed by the researchers consists of the LAMP2B gene contained in a virus capable of entering heart cells. The encouraging results of the research have allowed the experimentation to continue and a further study on male patients with Danon disease will soon begin in Europe. The only center in Italy invited to participate will be the AOU Meyer.

May 25, 2024|

Myectomy and mitral plastic surgery, the most effective therapy for young patients

The Hypertrophic Obstructive Cardiomyopathy Treatment course is designed to present the impact of obstruction on the quality of life and prognosis of patients with hypertrophic obstructive cardiomyopathy. The experiences gained so far with "classic" drugs, such as beta-blockers capable of effectively and safely reducing outflow obstruction and, in some cases, postponing or avoiding surgery, will be discussed. Over the last 2 decades, cardiac surgical experience with myectomy and mitral plasty have significantly improved patients' symptoms and their prognosis. With the introduction of Mavacamten, already available for "compassionate use" for patients over 18 years of age, and perhaps Aficamten in the future, there are prospects for long-term treatment, which currently makes it more suitable for elderly patients and in the future, perhaps, also in young patients, in whom cardiac surgery currently remains a fundamental solution.

May 25, 2024|

Gene therapy for hypertrophic cardiomyopathy, what's new

Cardiomyopathies are a group of diseases that affect the heart muscle, causing impaired function of the heart muscle and even dangerous complications. Despite the efforts of medical research, to date there is no definitive cure. Research is also focusing on gene therapies that aim to correct the genetic mutations underlying some forms of cardiomyopathy. Informing correctly on the one hand avoids generating false expectations in patients, while on the other it supports funding and efforts of the scientific community. For these reasons AICARM inaugurates a new column which will present the news and developments for the treatment of cardiomyopathies. We will present works that come from institutions and pharmaceutical companies, both Italian and foreign, always with authority and independence from the market, and in favor of patients with cardiomyopathy and their doctors.

May 18, 2024|

Risk assessment of beta-blockers in pregnant women with cardiomyopathy

Therapy during pregnancy involves the use of various drugs including the beta-blocker family, used in the treatment of some cardiomyopathies, cardiac arrhythmias and arterial hypertension. They are not responsible for an increase in the risk of birth defects, so in most cases pharmacological treatment during pregnancy is not only not contraindicated, but is absolutely recommended to maintain good clinical compensation of Cardiomyopathy, of fundamental importance for the regular progress of the pregnancy itself. In any case, management of these pregnancies by a multidisciplinary group that includes specialists in cardiology, obstetrics, obstetric ultrasound and echocardiography, perinatal toxicology, paediatrics is indicated.

April 27 2024|

Comment on the genetic survey (published in the March 2024 Newsletter)

We publish the comment of Dr. Francesca Torricelli, geneticist and former director of the Genetic Diagnostic Unit of the Careggi University Hospital, relating to the results of the survey on the availability of genetic testing at the main Italian Medical Genetics laboratories of the NHS for patients with Cardiomyopathies published on Aicarm News of March 2024.

April 26 2024|

The availability of genetic testing for cardiomyopathies in Italy

The results of a survey on the availability of genetic testing at the main Italian medical genetics laboratories of the NHS for patients with cardiomyopathies. Together with AICARM Aps, Dr. Maria Iascone (director of the Medical Genetics Laboratory of the ASTT Papa Giovanni XXIII of Bergamo) and Dr. Francesca Girolami (Cardiogenetics of the Meyer IRCCS University Hospital, of Florence). These are the most important conclusions: in most cases the test is carried out together with genetic counselling, it requires an average of 3-6 months to carry out and is always carried out with NGS technology.

March 21 2024|

What happens when we take a drug: Placebo and Nocebo effects

Whenever a drug is used for the first time in the treatment of diseases, the patient is faced with two possible effects. The "placebo effect", i.e. a perceived or real benefit on the part of the patient who believes he is undergoing an effective treatment for his clinical condition even if the medicine does not contain active properties. It is the "nocebo" effect (from the Latin "nocere", to damage), that is, the disturbing shadow of side effects. The detailed information leaflets of medicines, the so-called "leaflets", list a long list of possible negative health effects. These fears, fueled by negative expectations, can trigger the phenomenon. The tools to overcome the problem are correct information and the relationship of trust between doctor and patient.

March 21 2024|

Mavacamten ready for “compassionate use”, perhaps in a year it will be refundable

Mavacamten and Aficamten are the two new drugs for the treatment of hypertrophic cardiomyopathy. Mavacamten has entered the “compassionate” use phase. This means that the drug is already available and can be supplied by the manufacturer for patients with hypertrophic obstructive cardiomyopathy, upon request by expert cardiologists. Aficamten is a little further behind in the experimentation process.

February 21 2024|
Back to the top